FIB-4 Index (Liver Fibrosis)

The FIB-4 Index Calculator is a non-invasive fibrosis assessment tool that estimates the degree of liver fibrosis using four readily available parameters: age, AST, ALT, and platelet count. Developed by Sterling et al. in 2006 initially for HIV/HCV co-infected patients, the FIB-4 has been extensively validated across multiple liver disease etiologies including chronic hepatitis C, chronic hepatitis B, non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease. It has become one of the most widely recommended initial fibrosis screening tools in clinical practice guidelines worldwide.

The formula is: FIB-4 = (Age x AST) / (Platelet Count x sqrt(ALT)). The biological rationale underlying this formula integrates multiple aspects of liver fibrosis pathophysiology. Age reflects cumulative duration of liver injury and fibrosis progression. AST elevation reflects hepatocellular damage and is released from both cytoplasm and mitochondria, with the mitochondrial fraction increasing with more severe injury. The AST/ALT ratio tends to increase with advancing fibrosis as ALT clearance decreases. Platelet count decreases with advancing fibrosis due to reduced thrombopoietin production by the fibrotic liver and portal hypertension-related splenic sequestration.

The FIB-4 score stratifies patients into three categories using validated cutoff values. A FIB-4 below 1.30 indicates low probability of advanced fibrosis (negative predictive value 90-95%), effectively ruling out significant fibrosis and potentially avoiding the need for liver biopsy or more expensive non-invasive tests. A FIB-4 above 2.67 indicates high probability of advanced fibrosis or cirrhosis (positive predictive value 65-80%), warranting further evaluation and management. Values between 1.30 and 2.67 are indeterminate and require additional assessment with elastography (FibroScan) or other non-invasive tests.

The clinical utility of the FIB-4 lies in its ability to serve as a first-line screening tool in primary care and general practice. Given that NAFLD affects approximately 25% of the global adult population and is rapidly becoming the leading cause of chronic liver disease, there is an urgent need for simple, inexpensive screening tools to identify patients with advanced fibrosis who are at risk for complications. The FIB-4 requires only a standard blood test and patient age, making it universally accessible. Major hepatology societies including AASLD, EASL, and AGA recommend FIB-4 as part of the initial evaluation pathway for suspected NAFLD.

In the context of hepatitis C, the FIB-4 has been used to guide treatment urgency and post-treatment monitoring. Patients with FIB-4 values indicating advanced fibrosis are prioritized for antiviral treatment and require ongoing surveillance for hepatocellular carcinoma even after achieving sustained virological response. The index has also been valuable in screening large populations, such as veterans or blood donors, for undiagnosed significant liver fibrosis.

Limitations of the FIB-4 include reduced accuracy in patients under 35 or over 65 years old, in acute liver injury flares where transaminases are dramatically elevated, and in conditions affecting platelet count independent of liver disease (e.g., immune thrombocytopenia, myeloproliferative disorders). The indeterminate zone (1.30-2.67) encompasses approximately 30-40% of patients, requiring additional testing. Despite these limitations, the FIB-4 remains the most cost-effective initial step in the fibrosis assessment cascade.